Biogened S.A.

WSE:BGD 株式レポート

時価総額:zł54.0m

Biogened 過去の業績

過去 基準チェック /46

Biogenedは、平均年間31%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間12.9% 19.3%収益成長率で 成長しています。 Biogenedの自己資本利益率は12.4%であり、純利益率は4.5%です。

主要情報

31.0%

収益成長率

33.2%

EPS成長率

Pharmaceuticals 業界の成長29.4%
収益成長率19.3%
株主資本利益率12.4%
ネット・マージン4.5%
前回の決算情報30 Sep 2024

最近の業績更新

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Recent updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

収支内訳

Biogened の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

WSE:BGD 収益、費用、利益 ( )PLN Millions
日付収益収益G+A経費研究開発費
30 Sep 241075640
30 Jun 241065610
31 Mar 241004580
31 Dec 23965550
30 Sep 23924470
30 Jun 23904460
31 Mar 23854450
31 Dec 22803420
30 Sep 22774410
30 Jun 22724360
31 Mar 22703360
31 Dec 21652350
30 Sep 21572330
30 Jun 21542330
31 Mar 21501300
31 Dec 20481300
30 Sep 20492290
30 Jun 20481290
31 Mar 20481290
31 Dec 19471280
30 Sep 19451280
30 Jun 19441270
31 Mar 19411260
31 Dec 18401260
30 Sep 18391240
30 Jun 18391240
31 Mar 18361220
31 Dec 17341210
30 Sep 17301190
30 Jun 17311200
31 Mar 17291190
31 Dec 16291190
30 Sep 16322210
30 Jun 16312200
31 Mar 16313190
31 Dec 15303180
30 Sep 15302180
30 Jun 15261150
31 Mar 15241140
31 Dec 14231130
30 Sep 14201120
30 Jun 14211120
31 Mar 14221130
31 Dec 13222120

質の高い収益: BGDは 高品質の収益 を持っています。

利益率の向上: BGDの現在の純利益率 (4.5%)は、昨年(4.1%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: BGDの収益は過去 5 年間で年間31%増加しました。

成長の加速: BGDの過去 1 年間の収益成長率 ( 28.6% ) は、5 年間の平均 ( 年間31%を下回っています。

収益対業界: BGDの過去 1 年間の収益成長率 ( 28.6% ) はPharmaceuticals業界8.9%を上回りました。


株主資本利益率

高いROE: BGDの 自己資本利益率 ( 12.4% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘